120042-09-3

Basic information

• Product Name: N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate
• Synonyms: N-[(1,1-Dimethylethoxy)carbonyl]-L-homoserine Methyl Ester 4-Methylbenzenesulfonat;N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate;(S)-N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate;N-[(1,1-Dimethylethoxy)carbonyl]-L-homoserine Methyl Ester 4-Methylbenzenesulfonate;(S)-N-Boc-L-hoMoserine Methyl Ester Tosylate
• CAS NO: 120042-09-3
• Molecular Formula: C₁₇H₂₅NO₇S
• Molecular Weight: 387.45
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Chiral Reagents;Sulfur & Selenium Compounds;Mutagenesis Research Chemicals
• Mol File: 120042-09-3.mol

Chemical Properties

• Boiling Point: 532.7±50.0 °C(Predicted)
• Appearance: /
• Density: 1.216±0.06 g/cm3(Predicted)
• Solubility: Chloroform, Methanol
• PKA: 10.83±0.46(Predicted)
• CAS DataBase Reference: N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate(120042-09-3)
• EPA Substance Registry System: N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate(120042-09-3)

Safety Data

• Hazardous Substances Data: 120042-09-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate is used as a synthetic intermediate for the creation of azidohomoalanine, a functionalizable methionine surrogate. N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate plays a vital role in the development of novel pharmaceuticals and bioactive molecules, contributing to the advancement of drug discovery and therapeutic applications.
Used in Organic Chemistry:
In the field of organic chemistry, N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate is utilized as a key building block for the synthesis of complex organic molecules. Its unique structure and reactivity make it a valuable asset in the design and synthesis of new compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Research and Development:
N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate is also employed in research and development laboratories, where it is used to study the properties and reactivity of various organic compounds. N-Boc-L-homoserine Methyl Ester 4-Methylbenzenesulfonate serves as a model system for understanding the behavior of similar molecules and can be used to develop new synthetic methods and strategies in organic chemistry.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 120042-11-7 methyl (S)-4-hydroxy-2-((tert-butoxy)carbonylamino)-butyrate 
• 41088-86-2 L-2-(tert-butyloxycarbonylamino)-4-hydroxybutyric acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 124754-72-9 N-(tert-butyldimethylsilyloxycarbonyl)-O-(p-tolylsulfonyl)-L-homoserine methyl ester 

Relevant articles and documents

Synthesis and Biological Evaluation of CF3Se-Substituted α-Amino Acid Derivatives

Several CF3Se-substituted α-amino acid derivatives, such as (R)-2-amino-3-((trifluoromethyl)selanyl)propanoates (5 a/6 a), (S)-2-amino-4-((trifluoromethyl)selanyl)butanoates (5 b/6 b), (2R,3R)-2-amino-3-((trifluoromethyl)selanyl)butanoates (5 c/6 c), (R)-2-((S)-2-amino-3-phenylpropanamido)-3-((trifluoromethyl)selanyl)propanoates (11 a/12 a), and (R)-2-(2-aminoacetamido)-3-((trifluoromethyl)selanyl)propanoates (11 b/12 b), were readily synthesized from natural amino acids and [Me4N][SeCF3]. The primary in vitro cytotoxicity assays revealed that compounds 6 a, 11 a and 12 a were more effective cell growth inhibitors than the other tested CF3Se-substituted derivatives towards MCF-7, HCT116, and SK-OV-3 cells, with their IC50 values being less than 10 μM for MCF-7 and HCT116 cells. This study indicated the potentials of CF3Se moiety as a pharmaceutically relevant group in the design and synthesis of novel biologically active molecules.

Selenium-containing compound and preparation and application thereof

The invention discloses a compound shown as a formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereoisomer, raceme, solvate, hydrate, polymorph, prodrug or isotope variant thereof,a mixture of the substances, and a novel selenium-contai